🚀 VC round data is live in beta, check it out!
Zhangzhou Pientzehuang Valuation Multiples
Discover revenue and EBITDA valuation multiples for Zhangzhou Pientzehuang and similar public comparables like Sino Biopharmaceutical, CSPC Pharma Group, Alteogen, Neurocrine Biosciences and more.
Zhangzhou Pientzehuang Overview
About Zhangzhou Pientzehuang
Zhangzhou Pientzehuang Pharmaceutical Co Ltd produces and sells Chinese medicines. The company's product categories include tablets, hard capsules, granules, pills (water pills, honey pills), syrups, tinctures (including external use), ointments, lozenges, decoctions, Chinese herbal medicine slices (including direct oral slices) (clean preparation); production of candy products (candy), health food products; and production of beverages (solid beverages).
Founded
1999
HQ
Employees
2.8K
Website
Sectors
Financials (LTM)
EV
$13B
Zhangzhou Pientzehuang Financials
Zhangzhou Pientzehuang reported last 12-month revenue of $1B and EBITDA of $493M.
In the same LTM period, Zhangzhou Pientzehuang generated $585M in gross profit, $493M in EBITDA, and $385M in net income.
Revenue (LTM)
Zhangzhou Pientzehuang P&L
In the most recent fiscal year, Zhangzhou Pientzehuang reported revenue of $2B and EBITDA of $538M.
Zhangzhou Pientzehuang expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $585M | XXX | $675M | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 43% | XXX | XXX | XXX |
| EBITDA | $493M | XXX | $538M | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 32% | XXX | XXX | XXX |
| Net Profit | $385M | XXX | $436M | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 28% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Zhangzhou Pientzehuang Stock Performance
Zhangzhou Pientzehuang has current market cap of $13B, and enterprise value of $13B.
Market Cap Evolution
Zhangzhou Pientzehuang's stock price is $21.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13B | $13B | -1.2% | XXX | XXX | XXX | $0.72 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZhangzhou Pientzehuang Valuation Multiples
Zhangzhou Pientzehuang trades at 9.0x EV/Revenue multiple, and 26.6x EV/EBITDA.
EV / Revenue (LTM)
Zhangzhou Pientzehuang Financial Valuation Multiples
As of April 14, 2026, Zhangzhou Pientzehuang has market cap of $13B and EV of $13B.
Equity research analysts estimate Zhangzhou Pientzehuang's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zhangzhou Pientzehuang has a P/E ratio of 34.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13B | XXX | $13B | XXX | XXX | XXX |
| EV (current) | $13B | XXX | $13B | XXX | XXX | XXX |
| EV/Revenue | 9.0x | XXX | 8.3x | XXX | XXX | XXX |
| EV/EBITDA | 26.6x | XXX | 24.4x | XXX | XXX | XXX |
| EV/EBIT | 28.6x | XXX | 26.0x | XXX | XXX | XXX |
| EV/Gross Profit | 22.4x | XXX | 19.4x | XXX | XXX | XXX |
| P/E | 34.2x | XXX | 30.1x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 364.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zhangzhou Pientzehuang Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Zhangzhou Pientzehuang Margins & Growth Rates
Zhangzhou Pientzehuang's revenue in the last 12 month grew by 7%.
Zhangzhou Pientzehuang's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.1M for the same period.
Zhangzhou Pientzehuang's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zhangzhou Pientzehuang's rule of X is 51% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Zhangzhou Pientzehuang Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | (9%) | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | (11%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 51% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 11% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Zhangzhou Pientzehuang Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zhangzhou Pientzehuang | XXX | XXX | XXX | XXX | XXX | XXX |
| Sino Biopharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| CSPC Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Alteogen | XXX | XXX | XXX | XXX | XXX | XXX |
| Neurocrine Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Ionis Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zhangzhou Pientzehuang M&A Activity
Zhangzhou Pientzehuang acquired XXX companies to date.
Last acquisition by Zhangzhou Pientzehuang was on XXXXXXXX, XXXXX. Zhangzhou Pientzehuang acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Zhangzhou Pientzehuang
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialZhangzhou Pientzehuang Investment Activity
Zhangzhou Pientzehuang invested in XXX companies to date.
Zhangzhou Pientzehuang made its latest investment on XXXXXXXX, XXXXX. Zhangzhou Pientzehuang invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Zhangzhou Pientzehuang
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zhangzhou Pientzehuang
| When was Zhangzhou Pientzehuang founded? | Zhangzhou Pientzehuang was founded in 1999. |
| Where is Zhangzhou Pientzehuang headquartered? | Zhangzhou Pientzehuang is headquartered in China. |
| How many employees does Zhangzhou Pientzehuang have? | As of today, Zhangzhou Pientzehuang has over 2K employees. |
| Is Zhangzhou Pientzehuang publicly listed? | Yes, Zhangzhou Pientzehuang is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang trades under 600436 ticker. |
| When did Zhangzhou Pientzehuang go public? | Zhangzhou Pientzehuang went public in 2003. |
| Who are competitors of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang main competitors are Sino Biopharmaceutical, CSPC Pharma Group, Alteogen, Neurocrine Biosciences. |
| What is the current market cap of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang's current market cap is $13B. |
| What is the current revenue of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang's last 12 months revenue is $1B. |
| What is the current revenue growth of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Zhangzhou Pientzehuang? | Current revenue multiple of Zhangzhou Pientzehuang is 9.0x. |
| Is Zhangzhou Pientzehuang profitable? | Yes, Zhangzhou Pientzehuang is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang's last 12 months EBITDA is $493M. |
| What is Zhangzhou Pientzehuang's EBITDA margin? | Zhangzhou Pientzehuang's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Zhangzhou Pientzehuang? | Current EBITDA multiple of Zhangzhou Pientzehuang is 26.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.